Phenotypes associated with this allele

• Allele Symbol: Cd79a^tm1(cre)Reth
• Allele Name: targeted mutation 1, Michael Reth
• Allele ID: MGI:3687451
• Summary: 69 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
ht1	Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:3687461
cn2	Atmin^tm1.1Jhh/Atmin^tm1.1Jhh Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Cd79a^tm1(cre)Reth/Cd79a^+ Tg(IghMyc)22Bri/0	B6.Cg-Bcl2l11^tm1.1Ast Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh Tg(IghMyc)22Bri	MGI:5755464
cn3	Atmin^tm1.1Jhh/Atmin^tm1.1Jhh Cd79a^tm1(cre)Reth/Cd79a^+	B6.Cg-Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh	MGI:5755460
cn4	Atmin^tm1.1Jhh/Atmin^tm1.1Jhh Cd79a^tm1(cre)Reth/Cd79a^+ Tg(IghMyc)22Bri/0	B6.Cg-Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh Tg(IghMyc)22Bri	MGI:5755462
cn5	Cd79a^tm1(cre)Reth/Cd79a^+ Huwe1^tm1.1Mak/Y	B6.Cg-Cd79a^tm1(cre)Reth Huwe1^tm1.1Mak	MGI:5314905
cn6	Cd79a^tm1(cre)Reth/Cd79a^+ Dynll1^tm1.1Jhh/Dynll1^tm1.1Jhh	B6.Cg-Dynll1^tm1.1Jhh Cd79a^tm1(Cre)Reth	MGI:5755454
cn7	Cd79a^tm1(cre)Reth/Cd79a^+ Dynll1^tm1.1Jhh/Dynll1^tm1.1Jhh Tg(IghMyc)22Bri/0	B6.Cg-Dynll1^tm1.1Jhh Cd79a^tm1(Cre)Reth Tg(IghMyc)22Bri	MGI:5755458
cn8	Cd79a^tm1(cre)Reth/Cd79a^+ Nr4a1^tm1Pcn/Nr4a1^tm1Pcn	involves: 129 * BALB/c	MGI:6717461
cn9	Cd79a^tm1(cre)Reth/Cd79a^+ Nr4a1^tm1Pcn/Nr4a1^tm1Pcn Nr4a3^em1Juz/Nr4a3^em1Juz	involves: 129 * BALB/c * C57BL/6	MGI:6717460
cn10	Grk2^tm1Gwd/Grk2^tm1Gwd Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129 * BALB/c * C57BL/6	MGI:5295055
cn11	Cd79a^tm1(cre)Reth/Cd79a^+ Inpp5d^tm1Rav/Inpp5d^tm1Rav	involves: 129 * BALB/c * C57BL/6	MGI:6376530
cn12	Inpp5d^tm1Rav/Inpp5d^tm1Rav Cd79a^tm1(cre)Reth/Cd79a^+ Tg(IghAb36-65)1Wys/0	involves: 129 * BALB/c * C57BL/6 * FVB/N	MGI:6376533
cn13	Cd79a^tm1(cre)Reth/Cd79a^+ Gt(ROSA)26Sor^tm1(Ccnd2)Goos/Gt(ROSA)26Sor^tm1(Ccnd2)Goos Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * 129S6/SvEvTac * BALB/c * C57BL/6NCrl	MGI:8290654
cn14	Ikzf1^tm3.1Mbu/Ikzf1^tm3.1Mbu Cd79a^tm1(cre)Reth/Cd79a^+ Rag2^tm1Fwa/Rag2^tm1Fwa	involves: 129P2/OlaHsd * 129S/SvEv * BALB/c * C57BL/6 * SJL	MGI:5698683
cn15	Srsf3^tm1Pjln/Srsf3^tm1Pjln Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129P2/OlaHsd * BALB/c	MGI:3687458
cn16	Cd79a^tm1(cre)Reth/Cd79a^+ Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * BALB/c	MGI:8290656
cn17	Cd79a^tm1(cre)Reth/Cd79a^+ Eif4a1^tm1.1Bea/Eif4a1^tm1.1Bea	involves: 129P2/OlaHsd * BALB/c * C57BL/6	MGI:7646987
cn18	Syk^tm1Kuro/Syk^tm1Kuro Zap70^tm1Dlo/Zap70^tm1Dlo Cd79a^tm1(cre)Reth/?	involves: 129P2/OlaHsd * BALB/c * C57BL/6	MGI:3797235
cn19	Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Trp53^tm1Brn/Trp53^tm1Brn Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129P2/OlaHsd * BALB/c * C57BL/6	MGI:5463974
cn20	Hdac1^tm1.1Pmt/Hdac1^tm1.1Pmt Hdac2^tm1.1Pmt/Hdac2^tm1.1Pmt Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129P2/OlaHsd * BALB/c * C57BL/6 * FVB/N	MGI:4440609
cn21	Commd8^tm1.1Ksuz/Commd8^tm1.1Ksuz Igh^tm1Mnz/Igh^+ Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129P2/OlaHsd * BALB/c * C57BL/6NSlc * SJL	MGI:6358358
cn22	Cd79a^tm1(cre)Reth/Cd79a^+ Ikzf1^tm3.1Mbu/Ikzf1^tm3.1Mbu	involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL	MGI:5698681
cn23	Cd79a^tm1(cre)Reth/Cd79a^+ Ctnnbl1^tm1.1Crad/Ctnnbl1^tm1.1Crad	involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL	MGI:5795709
cn24	Cd79a^tm1(cre)Reth/Cd79a^+ Huwe1^tm1.1Mak/Y Trp53^tm1Brn/Trp53^tm1Brn	involves: 129P2/OlaHsd * C57BL/6 * SJL	MGI:5314906
cn25	Cd79a^tm1(cre)Reth/Cd79a^+ Slc39a10^tm1.1Tfk/Slc39a10^tm1.1Tfk	involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J	MGI:6112652
cn26	Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Dicer1^tm1Mmk/Dicer1^tm1Mmk Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S1/Sv * BALB/c	MGI:3797396
cn27	Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S1/Sv * BALB/c * C57BL/6	MGI:5463975
cn28	Tbc1d10c^tm1.1Psou/Tbc1d10c^tm1.2Psou Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S2/SvPas * BALB/c * C57BL/6J	MGI:5578118
cn29	Cd79a^tm1(cre)Reth/Cd79a^tm1(cre)Reth Mzb1^tm1.1Rug/Mzb1^tm1.1Rug	involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL	MGI:6294908
cn30	Blnk^tm1Pjln/Blnk^tm1Pjln Cd79a^tm1(cre)Reth/Cd79a^tm1(cre)Reth Mzb1^tm1.1Rug/Mzb1^tm1.1Rug	involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL	MGI:6294907
cn31	Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk Traf3ip2^tm2Sbn/Traf3ip2^tm2Sbn Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S4/SvJae * BALB/c * C57BL/6	MGI:5462351
cn32	Dnmt1^tm2Jae/Dnmt1^tm2Jae Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S4/SvJae * BALB/c * C57BL/6	MGI:3687459
cn33	Cnn2^tm1.1Jin/Cnn2^tm1.1Jin Cnn3^tm1.1Hjum/Cnn3^tm1.1Hjum Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S6/SvEvTac * 129X1/SvJ * BALB/c	MGI:5825469
cn34	Cnn3^tm1.1Hjum/Cnn3^tm1.1Hjum Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S6/SvEvTac * BALB/c	MGI:5825467
cn35	Gt(ROSA)26Sor^tm2(CAG-Notch2*)Uzs/Gt(ROSA)26Sor^+ Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S6/SvEvTac * BALB/c * C57BL/6J	MGI:5301627
cn36	Ssb^tm1Rjma/Ssb^tm2.1Rjma Cd79a^tm1(cre)Reth/Cd79a^+	involves: 129S/SvEv * BALB/c	MGI:5569496
cn37	Cd79a^tm1(cre)Reth/Cd79a^+ Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor^+	involves: 129X1/SvJ * BALB/c * C57BL/6	MGI:3687456
cn38	Dicer1^tm1Mmk/Dicer1^tm1Mmk Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c	MGI:3797393
cn39	Nfatc1^tm1Rao/Nfatc1^tm1Rao Nfatc2^tm1Rao/Nfatc2^tm1Rao Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c	MGI:5295256
cn40	Nfatc1^tm1Rao/Nfatc1^tm1Rao Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c	MGI:5295253
cn41	Dicer1^tm1Mmk/Dicer1^tm1.1Mmk Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c	MGI:3797392
cn42	Dicer1^tm1Mmk/Dicer1^tm1Mmk Tg(IghelMD4)4Ccg/0 Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c	MGI:3797394
cn43	Grb2^tm1Lnit/Grb2^tm1Lnit Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * BALB/cJ	MGI:4949890
cn44	Ikbkg^tm1.1Mpa/Ikbkg^tm1.1Mpa Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:3687508
cn45	Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:5463972
cn46	Cd79a^tm1(cre)Reth/Cd79a^+ Nfkbiz^tm1.1Muta/Nfkbiz^tm1.1Muta	involves: BALB/c * C57BL/6	MGI:5501491
cn47	Cd79a^tm1(cre)Reth/Cd79a^+ Was^tm1.1Ldn/Was^tm1.1Ldn	involves: BALB/c * C57BL/6	MGI:5319484
cn48	Stim1^tm1Kuro/Stim1^tm1Kuro Stim2^tm1.1Kuro/Stim2^tm1.1Kuro Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:5008567
cn49	Stim1^tm1Kuro/Stim1^tm1Kuro Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:5008566
cn50	Gt(ROSA)26Sor^tm1.1(Ubc-BCL3)Sbn/Gt(ROSA)26Sor^+ Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:5574306
cn51	Tcf3^tm1(PBX1)Mlc/Tcf3^+ Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:5825357
cn52	Cd79a^tm1(cre)Reth/Cd79a^+ Was^tm1.1Ldn/Y	involves: BALB/c * C57BL/6	MGI:5319485
cn53	Cd79a^tm1(cre)Reth/Cd79a^+ Was^tm1.1Ldn/Was^+	involves: BALB/c * C57BL/6	MGI:5319486
cn54	Stim2^tm1.1Kuro/Stim2^tm1.1Kuro Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6	MGI:5008568
cn55	Cd79a^tm1(cre)Reth/Cd79a^+ Phf5a^tm1.1Oux/Phf5a^tm1.1Oux Tg(IghelMD4)4Ccg/0	involves: BALB/c * C57BL/6 * C57BL/6J	MGI:7611733
cn56	Bcl6^tm1.1Mtto/Bcl6^tm1.1Mtto Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6 * C57BL/6JJcl	MGI:5461328
cn57	Bcl6^tm1.1Mtto/Bcl6^tm1.1Mtto Cd79a^tm1(cre)Reth/Cd79a^+ Tg(Cd4-cre)1Cwi/0	involves: BALB/c * C57BL/6 * C57BL/6JJcl * DBA/2	MGI:5461331
cn58	Cd79a^tm1(cre)Reth/Cd79a^+ Eif4b^tm1.1Tnr/Eif4b^tm1.1Tnr Eif4h^tm1c(EUCOMM)Wtsi/Eif4h^tm1c(EUCOMM)Wtsi	involves: BALB/c * C57BL/6 * C57BL/6N	MGI:7646989
cn59	Cd79a^tm1(cre)Reth/Cd79a^+ Phf5a^tm1.1Oux/Phf5a^tm1.1Oux	involves: BALB/c * C57BL/6J	MGI:7611716
cn60	Cd79a^tm1(cre)Reth/Cd79a^+ Orai1^tm1Smua/Orai1^tm1Smua	involves: BALB/c * C57BL/6J	MGI:7625698
cn61	Cd79a^tm1(cre)Reth/Cd79a^+ Orai1^tm1Smua/Orai1^tm1Smua Orai3^em1.1Treb/Orai3^em1.1Treb	involves: BALB/c * C57BL/6J * C57BL/6N	MGI:7625702
cn62	Cd79a^tm1(cre)Reth/Cd79a^+ Orai3^em1.1Treb/Orai3^em1.1Treb	involves: BALB/c * C57BL/6J * C57BL/6N	MGI:7625703
cn63	Cd79a^tm1(cre)Reth/Cd79a^+ Dicer1^tm1Mmk/Dicer1^tm1Mmk Tg(BCL2)22Wehi/0	involves: BALB/c * C57BL/6JWehi * SJL/JWehi	MGI:3797395
cn64	Rnf31^tm1.1Kiwa/Rnf31^tm1.1Kiwa Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6NCrlj * CBA/JNCrlj	MGI:5550380
cn65	Cd79a^tm1(cre)Reth/Cd79a^+ Commd3^tm1.1Ksuz/Commd3^tm1.1Ksuz	involves: BALB/c * C57BL/6NSlc * SJL	MGI:6358355
cn66	Cd79a^tm1(cre)Reth/Cd79a^+ Commd8^tm1.1Ksuz/Commd8^tm1.1Ksuz	involves: BALB/c * C57BL/6NSlc * SJL	MGI:6358356
cn67	Sh3kbp1^tm1Kuro/Sh3kbp1^tm1Kuro Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6 * NZB	MGI:5296787
cn68	Sh3kbp1^tm1Kuro/Sh3kbp1^tm1Kuro Cd79a^tm1(cre)Reth/Cd79a^+ Gt(ROSA)26Sor^tm4(Ikbkb)Rsky/?	involves: BALB/c * C57BL/6 * NZB	MGI:5296788
cn69	Ebf1^tm1.1Rug/Ebf1^tm1.1Rug Cd79a^tm1(cre)Reth/Cd79a^+	involves: BALB/c * C57BL/6 * SJL	MGI:5316371

Genotype
MGI:3687461

ht1

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

normal phenotype

no abnormal phenotype detected ( J:113645 )

• numbers of cells in B subfractions in spleen and bone marrow is unchanged vs wild-type

Genotype
MGI:5755464

cn2

• Allelic Composition: Atmin^tm1.1Jhh/Atmin^tm1.1Jhh; Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast; Cd79a^tm1(cre)Reth/Cd79a⁺; Tg(IghMyc)22Bri/0
• Genetic Background: B6.Cg-Bcl2l11^tm1.1Ast Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh Tg(IghMyc)22Bri

neoplasm

increased lymphoma incidence ( J:230105 )

• compared with Tg(IghMyc)22Bri mice

Genotype
MGI:5755460

cn3

• Allelic Composition: Atmin^tm1.1Jhh/Atmin^tm1.1Jhh; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: B6.Cg-Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh

immune system

increased B cell apoptosis ( J:230105 )

• 2-fold

decreased B cell number ( J:230105 )

• 8-fold in the peripheral blood

decreased immature B cell number ( J:230105 )

• 10-fold compared with Cd79a^tm1(Cre)Reth/Cd79a⁺ or Tg(IghMyc)22Bri mice

decreased IgG1 level ( J:230105 )

hematopoietic system

increased B cell apoptosis ( J:230105 )

• 2-fold

decreased B cell number ( J:230105 )

• 8-fold in the peripheral blood

decreased immature B cell number ( J:230105 )

• 10-fold compared with Cd79a^tm1(Cre)Reth/Cd79a⁺ or Tg(IghMyc)22Bri mice

decreased IgG1 level ( J:230105 )

cellular

increased B cell apoptosis ( J:230105 )

• 2-fold

Genotype
MGI:5755462

cn4

• Allelic Composition: Atmin^tm1.1Jhh/Atmin^tm1.1Jhh; Cd79a^tm1(cre)Reth/Cd79a⁺; Tg(IghMyc)22Bri/0
• Genetic Background: B6.Cg-Cd79a^tm1(Cre)Reth Atmin^tm1.1Jhh Tg(IghMyc)22Bri

immune system

increased B cell apoptosis ( J:230105 )

• 15-fold

decreased B cell number ( J:230105 )

• 7.5-fold compared with Tg(IghMyc)22Bri mice

decreased immature B cell number ( J:230105 )

• 60-fold compared with Cd79a^tm1(Cre)Reth/Cd79a⁺ or Tg(IghMyc)22Bri mice

neoplasm

decreased lymphoma incidence ( J:230105 )

• compared with Tg(IghMyc)22Bri mice

increased tumor latency ( J:230105 )

• compared with Tg(IghMyc)22Bri mice

• however, the range to tumor types is the same

cellular

increased B cell apoptosis ( J:230105 )

• 15-fold

hematopoietic system

increased B cell apoptosis ( J:230105 )

• 15-fold

decreased B cell number ( J:230105 )

• 7.5-fold compared with Tg(IghMyc)22Bri mice

decreased immature B cell number ( J:230105 )

• 60-fold compared with Cd79a^tm1(Cre)Reth/Cd79a⁺ or Tg(IghMyc)22Bri mice

Genotype
MGI:5314905

cn5

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Huwe1^tm1.1Mak/Y
• Genetic Background: B6.Cg-Cd79a^tm1(cre)Reth Huwe1^tm1.1Mak

immune system

increased B cell apoptosis ( J:181705 )

♂ • in pre-B cells and mature B cells (1.5-fold)

decreased B cell proliferation ( J:181705 )

♂ • of transitional, marginal zone and follicular B cells

♂ • when B cells are stimulated with anti-IgM or anti-IgM plus anti-CD40

♂ • in B cells stimulated with LPS plus IL4

abnormal B cell differentiation ( J:181705 )

♂ • partially blocked at pre-B stage

abnormal class switch recombination ( J:181705 )

♂ • following stimulation of B cells with LPS or LPS plus IL4

decreased transitional stage B cell number ( J:181705 )

♂

decreased mature B cell number ( J:181705 )

♂ • 3-fold for recirculating mature B cells due to increased apoptosis

♂ • of B220+IgM+ B cells in the spleen

absent B-1a cells ( J:181705 )

♂ • virtually absent in the peritoneal cavity

decreased follicular B cell number ( J:181705 )

♂

decreased marginal zone B cell number ( J:181705 )

♂

decreased pre-B cell number ( J:181705 )

♂ • due to increased apoptosis

abnormal humoral immune response ( J:181705 )

♂ • mice stimulated with a T-independent antigen, TNP-Ficoll, fail to mount a TNP-specific IgM or IgG3 unlike control mice

♂ • mice stimulated with a T-dependent antigen, NP(15)CGG, produce less NP-specific IgG1 compared with control mice

decreased IgA level ( J:181705 )

♂ • 4.5-fold in unstimulated mice

decreased IgG1 level ( J:181705 )

♂ • 2-fold in unstimulated mice

♂ • in mice stimulated with NP(15)CGG

decreased IgG2a level ( J:181705 )

♂ • 32-fold in unstimulated mice

decreased IgG3 level ( J:181705 )

♂ • 37-fold in unstimulated mice

♂ • in mice stimulated with TNP-Ficoll

decreased IgM level ( J:181705 )

♂ • 2.5-fold in unstimulated mice

♂ • in mice stimulated with TNP-Ficoll

increased susceptibility to Riboviria infection ( J:181705 )

♂ • mice infected with vesicular stomatitis virus (VSV) exhibit delayed anti-VSV antibody production and reduced anti-VSV IgG levels compared with control mice

cellular

increased B cell apoptosis ( J:181705 )

♂ • in pre-B cells and mature B cells (1.5-fold)

decreased B cell proliferation ( J:181705 )

♂ • of transitional, marginal zone and follicular B cells

♂ • when B cells are stimulated with anti-IgM or anti-IgM plus anti-CD40

♂ • in B cells stimulated with LPS plus IL4

hematopoietic system

increased B cell apoptosis ( J:181705 )

♂ • in pre-B cells and mature B cells (1.5-fold)

decreased B cell proliferation ( J:181705 )

♂ • of transitional, marginal zone and follicular B cells

♂ • when B cells are stimulated with anti-IgM or anti-IgM plus anti-CD40

♂ • in B cells stimulated with LPS plus IL4

abnormal B cell differentiation ( J:181705 )

♂ • partially blocked at pre-B stage

abnormal class switch recombination ( J:181705 )

♂ • following stimulation of B cells with LPS or LPS plus IL4

decreased transitional stage B cell number ( J:181705 )

♂

decreased mature B cell number ( J:181705 )

♂ • 3-fold for recirculating mature B cells due to increased apoptosis

♂ • of B220+IgM+ B cells in the spleen

absent B-1a cells ( J:181705 )

♂ • virtually absent in the peritoneal cavity

decreased follicular B cell number ( J:181705 )

♂

decreased marginal zone B cell number ( J:181705 )

♂

decreased pre-B cell number ( J:181705 )

♂ • due to increased apoptosis

decreased IgA level ( J:181705 )

♂ • 4.5-fold in unstimulated mice

decreased IgG1 level ( J:181705 )

♂ • 2-fold in unstimulated mice

♂ • in mice stimulated with NP(15)CGG

decreased IgG2a level ( J:181705 )

♂ • 32-fold in unstimulated mice

decreased IgG3 level ( J:181705 )

♂ • 37-fold in unstimulated mice

♂ • in mice stimulated with TNP-Ficoll

decreased IgM level ( J:181705 )

♂ • 2.5-fold in unstimulated mice

♂ • in mice stimulated with TNP-Ficoll

Genotype
MGI:5755454

cn6

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Dynll1^tm1.1Jhh/Dynll1^tm1.1Jhh
• Genetic Background: B6.Cg-Dynll1^tm1.1Jhh Cd79a^tm1(Cre)Reth

immune system

abnormal B cell morphology ( J:230105 )

• 2-fold in pro-B/pre-B

decreased immature B cell number ( J:230105 )

• 8-fold in the bone marrow

decreased mature B cell number ( J:230105 )

• 4-fold in the spleen

decreased pre-B cell number ( J:230105 )

• in the bone marrow

hematopoietic system

abnormal B cell morphology ( J:230105 )

• 2-fold in pro-B/pre-B

decreased immature B cell number ( J:230105 )

• 8-fold in the bone marrow

decreased mature B cell number ( J:230105 )

• 4-fold in the spleen

decreased pre-B cell number ( J:230105 )

• in the bone marrow

Genotype
MGI:5755458

cn7

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Dynll1^tm1.1Jhh/Dynll1^tm1.1Jhh; Tg(IghMyc)22Bri/0
• Genetic Background: B6.Cg-Dynll1^tm1.1Jhh Cd79a^tm1(Cre)Reth Tg(IghMyc)22Bri

immune system

decreased immature B cell number ( J:230105 )

• greater than 50-fold

neoplasm

decreased lymphoma incidence ( J:230105 )

• compared with Tg(IghMyc)22Bri mice

hematopoietic system

decreased immature B cell number ( J:230105 )

• greater than 50-fold

Genotype
MGI:6717461

cn8

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Nr4a1^tm1Pcn/Nr4a1^tm1Pcn
• Genetic Background: involves: 129 * BALB/c

cellular

increased B cell proliferation ( J:306652 )

• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ lymphocytes and anti-immunoglobulin M (anti-IgM)

hematopoietic system

increased B cell proliferation ( J:306652 )

• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ lymphocytes and anti-immunoglobulin M (anti-IgM)

immune system

increased B cell proliferation ( J:306652 )

• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ lymphocytes and anti-immunoglobulin M (anti-IgM)

Genotype
MGI:6717460

cn9

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Nr4a1^tm1Pcn/Nr4a1^tm1Pcn; Nr4a3^em1Juz/Nr4a3^em1Juz
• Genetic Background: involves: 129 * BALB/c * C57BL/6

cellular

decreased B cell apoptosis ( J:306652 )

• greater survival of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)

increased B cell proliferation ( J:306652 )

• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)

hematopoietic system

decreased B cell apoptosis ( J:306652 )

• greater survival of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)

increased B cell proliferation ( J:306652 )

• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)

immune system

immune system phenotype ( J:306652 )

N • normal T cell and B cell development and homeostasis

decreased B cell apoptosis ( J:306652 )

• greater survival of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)

increased B cell proliferation ( J:306652 )

• greater proliferation of CD45.2+ B cells when co-cultured for 72 hours with congenically marked wild-type CD45.1+ B cells and anti-immunoglobulin M (anti-IgM)

Genotype
MGI:5295055

cn10

• Allelic Composition: Grk2^tm1Gwd/Grk2^tm1Gwd; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129 * BALB/c * C57BL/6

immune system

decreased B cell number ( J:176118 )

• in the lymph nodes

increased B cell number ( J:176118 )

• in the spleen and blood

increased follicular B cell number ( J:176118 )

increased marginal zone B cell number ( J:176118 )

increased CD4-positive, alpha-beta T cell number ( J:176118 )

• in the spleen

increased CD8-positive, alpha-beta T cell number ( J:176118 )

• in the spleen

abnormal B cell physiology ( J:176118 )

• B cells and marginal zone B cells exhibit increased chemotactic response to S1P compared with control cells

• long-term accumulation of B cells in the lymph node is reduced compared with control cells

• marginal zone B cells exhibit decreased chemotactic response to CCL21 compared with control cells

• marginal zone B cells exhibit increased chemotactic response to SEW2871 (S1PR1-selective agonist) compared with control cells

• marginal zone B cell relocalization to the follicle induced by FTY720 treatment is delayed compared to in control mice

• splenic follicular dendritic cells exhibit reduced deposition of phycoerythrin-induced complexes compared with control cells

• however, transfer into a S1P null mouse restores normal lymph node accumulation

hematopoietic system

decreased B cell number ( J:176118 )

• in the lymph nodes

increased B cell number ( J:176118 )

• in the spleen and blood

increased follicular B cell number ( J:176118 )

increased marginal zone B cell number ( J:176118 )

increased CD4-positive, alpha-beta T cell number ( J:176118 )

• in the spleen

increased CD8-positive, alpha-beta T cell number ( J:176118 )

• in the spleen

abnormal B cell physiology ( J:176118 )

• B cells and marginal zone B cells exhibit increased chemotactic response to S1P compared with control cells

• long-term accumulation of B cells in the lymph node is reduced compared with control cells

• marginal zone B cells exhibit decreased chemotactic response to CCL21 compared with control cells

• marginal zone B cells exhibit increased chemotactic response to SEW2871 (S1PR1-selective agonist) compared with control cells

• marginal zone B cell relocalization to the follicle induced by FTY720 treatment is delayed compared to in control mice

• splenic follicular dendritic cells exhibit reduced deposition of phycoerythrin-induced complexes compared with control cells

• however, transfer into a S1P null mouse restores normal lymph node accumulation

Genotype
MGI:6376530

cn11

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Inpp5d^tm1Rav/Inpp5d^tm1Rav
• Genetic Background: involves: 129 * BALB/c * C57BL/6

mortality/aging

premature death ( J:178833 )

• mice have a less than 40% survival rate at 1 year

immune system

increased IgG level ( J:178833 )

• IgG deposition in kidney glomeruli is seen at 20 weeks of age

increased susceptibility to systemic lupus erythematosus ( J:178833 )

• mice show autoantibodies that are specifically seen in lupus; ssDNA, dsDNA, dsRNA and chromatin

increased autoantibody level ( J:178833 )

increased anti-nuclear antigen antibody level ( J:178833 )

• anti-nuclear antibodies in the sera in 20-week old mice

increased anti-chromatin antibody level ( J:178833 )

• mice exhibit chromatin autoantibodies at 8 weeks of age and at 20 weeks of age, mice show chromatin antibodies at amounts comparable to those seen in NZB/NZW mice

increased anti-double stranded DNA antibody level ( J:178833 )

increased anti-single stranded DNA antibody level ( J:178833 )

hematopoietic system

increased IgG level ( J:178833 )

• IgG deposition in kidney glomeruli is seen at 20 weeks of age

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
systemic lupus erythematosus		DOID:9074	OMIM:152700 OMIM:300809 OMIM:605480 OMIM:608437 OMIM:609903 OMIM:609939 OMIM:610065 OMIM:610066 OMIM:612254 OMIM:612378 OMIM:613145 OMIM:614420	J:178833

Genotype
MGI:6376533

cn12

• Allelic Composition: Inpp5d^tm1Rav/Inpp5d^tm1Rav; Cd79a^tm1(cre)Reth/Cd79a⁺; Tg(IghAb36-65)1Wys/0
• Genetic Background: involves: 129 * BALB/c * C57BL/6 * FVB/N

immune system

abnormal B cell negative selection ( J:178833 )

• peripheral B cell numbers are reduced by about 70%, suggesting enhanced negative selection

increased plasma cell number ( J:178833 )

• increase in frequency of plasma cells in the B cell population (4.96% of B cells compared to 0.04% in controls)

decreased B cell number ( J:178833 )

• peripheral B cell numbers are reduced by about 70%, suggesting enhanced negative selection

abnormal B cell anergy ( J:178833 )

• cell surface mIgM and mIgD are reduced 50% in B cells and B cells express reduced CD93, CD95, and CD80 indicating a loss of anergic B cells

• B cells lose features of anergy, including antigen unresponsiveness measured by BCR aggregation-induced Akt activation and calcium mobilization

• increase in frequency of B cells with activated phenotype (CD86+)

increased autoantibody level ( J:178833 )

• mice spontaneously express about 4-fold increased autoantibody by 20 weeks of age

hematopoietic system

abnormal B cell negative selection ( J:178833 )

• peripheral B cell numbers are reduced by about 70%, suggesting enhanced negative selection

increased plasma cell number ( J:178833 )

• increase in frequency of plasma cells in the B cell population (4.96% of B cells compared to 0.04% in controls)

decreased B cell number ( J:178833 )

• peripheral B cell numbers are reduced by about 70%, suggesting enhanced negative selection

Genotype
MGI:8290654

cn13

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Gt(ROSA)26Sor^{tm1(Ccnd2)Goos}/Gt(ROSA)26Sor^{tm1(Ccnd2)Goos}; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * 129S6/SvEvTac * BALB/c * C57BL/6NCrl

mortality/aging

decreased tumor-free survival time ( J:323008 )

• median survival of 269 d

neoplasm

abnormal tumor morphology ( J:323008 )

• more frequent infiltration of proliferating tumor cells in the small intestine compared to mutant mice not over-expressing Ccnd2

• in 9 of 17 mice lymphomas have a mantle cell lymphoma (MCL) like immunophenotype unlike mutant mice that do not over-express Ccnd2

• about half of mice show only MCL-like lymphomas while others carry a mix of MCL and non-MCL lymphomas

• tumor cells have B1-specific B-cell receptors and elevated B cell receptor signalling

increased lymphoma incidence ( J:323008 )

• develop lymphadenopathies significantly sooner compared to mutant mice that do not over-express Ccnd2

• lymphomas are frequently seen in peripheral lymphoid tissue including mandibular, axillary, inguinal, and mediastinal lymph nodes, and distributed throughout the body with infiltrations in the spleen, liver, peripheral blood, and small intestine

• lymphomas are IgM+IgD+

• these are aggressive and transplantable MCL-like tumors

immune system

immune system phenotype ( J:323008 )

N • no major abnormalities are seen in B2 cell development or in the expansion of B1a cells in tumor free mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
mantle cell lymphoma		DOID:0050746		J:323008

Genotype
MGI:5698683

cn14

• Allelic Composition: Ikzf1^tm3.1Mbu/Ikzf1^tm3.1Mbu; Cd79a^tm1(cre)Reth/Cd79a⁺; Rag2^tm1Fwa/Rag2^tm1Fwa
• Genetic Background: involves: 129P2/OlaHsd * 129S/SvEv * BALB/c * C57BL/6 * SJL

hematopoietic system

decreased pro-B cell number ( J:209928 )

• three fold fewer pro-B cells

immune system

decreased pro-B cell number ( J:209928 )

• three fold fewer pro-B cells

Genotype
MGI:3687458

cn15

• Allelic Composition: Srsf3^tm1Pjln/Srsf3^tm1Pjln; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/c

immune system

decreased pro-B cell number ( J:113645 )

• strong reduction in number of B cell precursors is seen in bone marrow

decreased B cell number ( J:113645 )

• drastic reductions in B cell number are found in spleen, thymus, and bone marrow

decreased pre-B cell number ( J:113645 )

• drastic reduction in pre-B cells indicates that Sfrs3 is required for pre-B cell survival

hematopoietic system

decreased pro-B cell number ( J:113645 )

• strong reduction in number of B cell precursors is seen in bone marrow

decreased B cell number ( J:113645 )

• drastic reductions in B cell number are found in spleen, thymus, and bone marrow

decreased pre-B cell number ( J:113645 )

• drastic reduction in pre-B cells indicates that Sfrs3 is required for pre-B cell survival

Genotype
MGI:8290656

cn16

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * BALB/c

mortality/aging

decreased tumor-free survival time ( J:323008 )

• median survival of 379 d

neoplasm

increased B cell derived lymphoma incidence ( J:323008 )

• B cell malignancies develop within 400 d in 58% (11 of 19) of mice

Genotype
MGI:7646987

cn17

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Eif4a1^tm1.1Bea/Eif4a1^tm1.1Bea
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6

hematopoietic system

decreased pro-B cell number ( J:344730 )

• greater than 20-fold reduction in pro B or Hardy Fraction B cells in the bone marrow

• remaining pro B cells have only a minor reduction in EIF4A1 and a 10-fold increase in EIF4A2

decreased B cell number ( J:344730 )

• almost complete loss of splenic B cells

immune system

decreased pro-B cell number ( J:344730 )

• greater than 20-fold reduction in pro B or Hardy Fraction B cells in the bone marrow

• remaining pro B cells have only a minor reduction in EIF4A1 and a 10-fold increase in EIF4A2

decreased B cell number ( J:344730 )

• almost complete loss of splenic B cells

Genotype
MGI:3797235

cn18

• Allelic Composition: Syk^tm1Kuro/Syk^tm1Kuro; Zap70^tm1Dlo/Zap70^tm1Dlo; Cd79a^tm1(cre)Reth/?
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6

immune system

abnormal pro-B cell differentiation ( J:134528 )

• there is a complete block pro-B cell differentation at the BP-1⁺HAS^low stage

hematopoietic system

abnormal pro-B cell differentiation ( J:134528 )

• there is a complete block pro-B cell differentation at the BP-1⁺HAS^low stage

Genotype
MGI:5463974

cn19

• Allelic Composition: Atmin^tm1.2Jhh/Atmin^tm1.2Jhh; Trp53^tm1Brn/Trp53^tm1Brn; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6

immune system

decreased B cell number ( J:191832 )

• in the spleen but not as severe as in Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

decreased immature B cell number ( J:191832 )

• in the bone marrow but not as severe as in Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

hematopoietic system

decreased B cell number ( J:191832 )

• in the spleen but not as severe as in Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

decreased immature B cell number ( J:191832 )

• in the bone marrow but not as severe as in Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

Genotype
MGI:4440609

cn20

• Allelic Composition: Hdac1^tm1.1Pmt/Hdac1^tm1.1Pmt; Hdac2^tm1.1Pmt/Hdac2^tm1.1Pmt; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6 * FVB/N

hematopoietic system

increased B cell apoptosis ( J:157903 )

• of pre BII cells and large pre BII cells

decreased pro-B cell number ( J:157903 )

• numbers of pre BI cells are reduced by 60%-80%

arrested B cell differentiation ( J:157903 )

• block in B cell differentiation as early as the pre BI cell stage only 4.5% of pre B cells are in S phase compared to 80% for wild-type cells

decreased bone marrow cell number ( J:157903 )

• only a very few B cells remain

decreased B cell number ( J:157903 )

• spleen is virtually empty of circulating mature B cells

• in bone marrow, only a very few B cells remain

decreased pre-B cell number ( J:157903 )

• fewer than 1% of pre BII cell stage cells remain

abnormal spleen morphology ( J:157903 )

• virtually empty of circulating mature B cells

immune system

increased B cell apoptosis ( J:157903 )

• of pre BII cells and large pre BII cells

decreased pro-B cell number ( J:157903 )

• numbers of pre BI cells are reduced by 60%-80%

arrested B cell differentiation ( J:157903 )

• block in B cell differentiation as early as the pre BI cell stage only 4.5% of pre B cells are in S phase compared to 80% for wild-type cells

decreased B cell number ( J:157903 )

• spleen is virtually empty of circulating mature B cells

• in bone marrow, only a very few B cells remain

decreased pre-B cell number ( J:157903 )

• fewer than 1% of pre BII cell stage cells remain

abnormal spleen morphology ( J:157903 )

• virtually empty of circulating mature B cells

cellular

increased B cell apoptosis ( J:157903 )

• of pre BII cells and large pre BII cells

Genotype
MGI:6358358

cn21

• Allelic Composition: Commd8^tm1.1Ksuz/Commd8^tm1.1Ksuz; Igh^tm1Mnz/Igh⁺; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6NSlc * SJL

immune system

abnormal spleen B cell follicle morphology ( J:278399 )

• 3 hours after antigen injection, B cells fail to accumulate in the outer follicle instead had already arrived at the B-T boundary unlike in control cells

• however, B cells are distributed at the B-T boundary after 6 hours

hematopoietic system

abnormal spleen B cell follicle morphology ( J:278399 )

• 3 hours after antigen injection, B cells fail to accumulate in the outer follicle instead had already arrived at the B-T boundary unlike in control cells

• however, B cells are distributed at the B-T boundary after 6 hours

Genotype
MGI:5698681

cn22

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Ikzf1^tm3.1Mbu/Ikzf1^tm3.1Mbu
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL

hematopoietic system

abnormal B cell differentiation ( J:209928 )

increased pro-B cell number ( J:209928 )

• two fold more pro-B cells than in controls

• proliferation of c-Kit^hi pro-B cells is normal

• c-Kit^lo pro-B cells accumulate in the G1-G0 phases of the cell cycle

• cells are smaller with functionally rearranged immunoglobulin mu

• c-Kit^hi pro-B cells expressing immunoglobulin mu are increased

abnormal B cell number ( J:209928 )

• six fold reduction in total B cell number in bone marrow relative to controls

decreased pre-B cell number ( J:209928 )

• nearly complete loss of pre-B cells

neoplasm

neoplasm ( J:209928 )

N • evidence of B cell leukemias is not observed during a year of observation

immune system

abnormal B cell differentiation ( J:209928 )

increased pro-B cell number ( J:209928 )

• two fold more pro-B cells than in controls

• proliferation of c-Kit^hi pro-B cells is normal

• c-Kit^lo pro-B cells accumulate in the G1-G0 phases of the cell cycle

• cells are smaller with functionally rearranged immunoglobulin mu

• c-Kit^hi pro-B cells expressing immunoglobulin mu are increased

abnormal B cell number ( J:209928 )

• six fold reduction in total B cell number in bone marrow relative to controls

decreased pre-B cell number ( J:209928 )

• nearly complete loss of pre-B cells

Genotype
MGI:5795709

cn23

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Ctnnbl1^tm1.1Crad/Ctnnbl1^tm1.1Crad
• Genetic Background: involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL

immune system

immune system phenotype ( J:232010 )

N • mice exhibit normal splenic B cells numbers and early stages of B cell differentiation

abnormal B cell proliferation ( J:232010 )

• delayed entry into S phase on activation of resting, affecting follicular more than marginal zone B cells

decreased B cell proliferation ( J:232010 )

• in response to LPS or anti-CD40 stimulation

abnormal class switch recombination ( J:232010 )

• reduced immunoglobin class switching in splenic B cells

hematopoietic system

abnormal B cell proliferation ( J:232010 )

• delayed entry into S phase on activation of resting, affecting follicular more than marginal zone B cells

decreased B cell proliferation ( J:232010 )

• in response to LPS or anti-CD40 stimulation

abnormal class switch recombination ( J:232010 )

• reduced immunoglobin class switching in splenic B cells

cellular

abnormal B cell proliferation ( J:232010 )

• delayed entry into S phase on activation of resting, affecting follicular more than marginal zone B cells

decreased B cell proliferation ( J:232010 )

• in response to LPS or anti-CD40 stimulation

Genotype
MGI:5314906

cn24

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Huwe1^tm1.1Mak/Y; Trp53^tm1Brn/Trp53^tm1Brn
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * SJL

immune system

immune system phenotype ( J:181705 )

♂N • bone marrow B cell development and stimulated and unstimulated splenic B cell proliferation are restored compared to in Cd79a^tm1(cre)Reth/Cd79a⁺ Huwe1^tm1.1Mak/Y mice

abnormal class switch recombination ( J:181705 )

♂ • to a greater extent than in Cd79a^tm1(cre)Reth/Cd79a⁺ Huwe1^tm1.1Mak/Y mice following stimulation of B cells with LPS or LPS plus IL4

absent B-1a cells ( J:181705 )

♂ • virtually absent in the peritoneal cavity

decreased IgG1 level ( J:181705 )

♂

decreased IgM level ( J:181705 )

♂

hematopoietic system

abnormal class switch recombination ( J:181705 )

♂ • to a greater extent than in Cd79a^tm1(cre)Reth/Cd79a⁺ Huwe1^tm1.1Mak/Y mice following stimulation of B cells with LPS or LPS plus IL4

absent B-1a cells ( J:181705 )

♂ • virtually absent in the peritoneal cavity

decreased IgG1 level ( J:181705 )

♂

decreased IgM level ( J:181705 )

♂

Genotype
MGI:6112652

cn25

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Slc39a10^tm1.1Tfk/Slc39a10^tm1.1Tfk
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J

hematopoietic system

decreased pro-B cell number ( J:213935 )

• decrease in B cell progenitors

decreased B cell number ( J:213935 )

• decrease in the number of CD19+ B cells in the spleen

spleen atrophy ( J:213935 )

decreased immunoglobulin level ( J:213935 )

decreased IgA level ( J:213935 )

decreased IgE level ( J:213935 )

decreased IgG1 level ( J:213935 )

decreased IgG2b level ( J:213935 )

decreased IgG2c level ( J:213935 )

decreased IgG3 level ( J:213935 )

decreased IgM level ( J:213935 )

immune system

decreased pro-B cell number ( J:213935 )

• decrease in B cell progenitors

decreased B cell number ( J:213935 )

• decrease in the number of CD19+ B cells in the spleen

spleen atrophy ( J:213935 )

decreased immunoglobulin level ( J:213935 )

decreased IgA level ( J:213935 )

decreased IgE level ( J:213935 )

decreased IgG1 level ( J:213935 )

decreased IgG2b level ( J:213935 )

decreased IgG2c level ( J:213935 )

decreased IgG3 level ( J:213935 )

decreased IgM level ( J:213935 )

Genotype
MGI:3797396

cn26

• Allelic Composition: Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast; Dicer1^tm1Mmk/Dicer1^tm1Mmk; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S1/Sv * BALB/c

immune system

decreased B cell number ( J:135783 )

• while B cell numbers are increased relative to in Cd79a^tm1(cre)Reth/Cd79a⁺ Bcl2l11^tm1.1Ast/Bcl2l11⁺ Dicer1^tm1Mmk/Dicer1^tm1Mmk mice, numbers are still lower than in wild-type mice

decreased mature B cell number ( J:135783 )

hematopoietic system

decreased B cell number ( J:135783 )

• while B cell numbers are increased relative to in Cd79a^tm1(cre)Reth/Cd79a⁺ Bcl2l11^tm1.1Ast/Bcl2l11⁺ Dicer1^tm1Mmk/Dicer1^tm1Mmk mice, numbers are still lower than in wild-type mice

decreased mature B cell number ( J:135783 )

Genotype
MGI:5463975

cn27

• Allelic Composition: Atmin^tm1.2Jhh/Atmin^tm1.2Jhh; Bcl2l11^tm1.1Ast/Bcl2l11^tm1.1Ast; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S1/Sv * BALB/c * C57BL/6

immune system

immune system phenotype ( J:191832 )

N • B cell development is rescued compared with Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

enlarged spleen ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased spleen weight ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased B cell number ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased immature B cell number ( J:191832 )

• compared with Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased pre-B cell number ( J:191832 )

• compared with Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

hematopoietic system

enlarged spleen ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased spleen weight ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased B cell number ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased immature B cell number ( J:191832 )

• compared with Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased pre-B cell number ( J:191832 )

• compared with Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

growth/size/body

enlarged spleen ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

increased spleen weight ( J:191832 )

• compared with control and Atmin^tm1.2Jhh/Atmin^tm1.2Jhh Cd79a^tm1(cre)Reth/Cd79a⁺ mice

Genotype
MGI:5578118

cn28

• Allelic Composition: Tbc1d10c^tm1.1Psou/Tbc1d10c^tm1.2Psou; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S2/SvPas * BALB/c * C57BL/6J

immune system

abnormal B cell physiology ( J:211913 )

• accelerated antigen-specific B cell response in vivo in response to ovalbumin

increased IgG level ( J:211913 )

• increased anti-ovalbumin IgG titer after ovalbumin treatment

• CpG-DNA-treated mice exhibit renal IgG deposits unlike wild-type mice

increased IgM level ( J:211913 )

• in ovalbumin-treated mice

increased susceptibility to systemic lupus erythematosus ( J:211913 )

• CpG-DNA-treated mice exhibit increased anti-double stranded DNA antibody levels and renal IgG deposits compared with control mice

increased anti-double stranded DNA antibody level ( J:211913 )

• in CpG-DNA-treated mice

• however, untreated mice do not produce autoantibodies

hematopoietic system

abnormal B cell physiology ( J:211913 )

• accelerated antigen-specific B cell response in vivo in response to ovalbumin

increased IgG level ( J:211913 )

• increased anti-ovalbumin IgG titer after ovalbumin treatment

• CpG-DNA-treated mice exhibit renal IgG deposits unlike wild-type mice

increased IgM level ( J:211913 )

• in ovalbumin-treated mice

Genotype
MGI:6294908

cn29

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a^tm1(cre)Reth; Mzb1^tm1.1Rug/Mzb1^tm1.1Rug
• Genetic Background: involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL

hematopoietic system

increased pro-B cell number ( J:211639 )

• increased percentage of B220+ CD43+ pro-B cells in bone marrow

increased late pro-B cell number ( J:211639 )

• increased percentage of B220+ CD19+ muHC- CD25- late pro-B cells in bone marrow

abnormal B cell number ( J:211639 )

• decrease in CD19+ B cells in splenic B cell compartment

• reduced frequency of peritoneal B cells

• reduced percentage of B220hi CD43- recirculating B cells in bone marrow

• reduced percentage of B220int CD43- pre-B cells in bone marrow

• reduced number of muHC+ cells in IL7+ bone marrow B cell cultures

• normal frequency of cells with intracellular muHC in IL7+ bone marrow B cell cultures

decreased pre-B cell number ( J:211639 )

• reduced CD25+ pre-B cell number in bone marrow

small spleen ( J:211639 )

immune system

increased pro-B cell number ( J:211639 )

• increased percentage of B220+ CD43+ pro-B cells in bone marrow

increased late pro-B cell number ( J:211639 )

• increased percentage of B220+ CD19+ muHC- CD25- late pro-B cells in bone marrow

abnormal B cell number ( J:211639 )

• decrease in CD19+ B cells in splenic B cell compartment

• reduced frequency of peritoneal B cells

• reduced percentage of B220hi CD43- recirculating B cells in bone marrow

• reduced percentage of B220int CD43- pre-B cells in bone marrow

• reduced number of muHC+ cells in IL7+ bone marrow B cell cultures

• normal frequency of cells with intracellular muHC in IL7+ bone marrow B cell cultures

decreased pre-B cell number ( J:211639 )

• reduced CD25+ pre-B cell number in bone marrow

small spleen ( J:211639 )

Genotype
MGI:6294907

cn30

• Allelic Composition: Blnk^tm1Pjln/Blnk^tm1Pjln; Cd79a^tm1(cre)Reth/Cd79a^tm1(cre)Reth; Mzb1^tm1.1Rug/Mzb1^tm1.1Rug
• Genetic Background: involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL

hematopoietic system

abnormal bone marrow cell physiology ( J:211639 )

• 2.5-fold reduction in frequency of muHC+ lambda5+ cells in bone marrow

• increase in lambda5+ only bone marrow cells

Genotype
MGI:5462351

cn31

• Allelic Composition: Fcgr2b^tm1Ttk/Fcgr2b^tm1Ttk; Traf3ip2^tm2Sbn/Traf3ip2^tm2Sbn; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S4/SvJae * BALB/c * C57BL/6

immune system

increased germinal center B cell number ( J:191090 )

• mutants exhibit an increase in percentage and the total number of germinal center B cells compared to wild-type mice, although the total number of germinal center B cells is lower than in Fcgr2b homozygotes (that are also heterozygous for the floxed Traf3ip2 allele)

increased plasma cell number ( J:191090 )

glomerulonephritis ( J:191090 )

• develop glomerulonephritis comparable to single Fcgr2b homozygotes

hematopoietic system

increased germinal center B cell number ( J:191090 )

• mutants exhibit an increase in percentage and the total number of germinal center B cells compared to wild-type mice, although the total number of germinal center B cells is lower than in Fcgr2b homozygotes (that are also heterozygous for the floxed Traf3ip2 allele)

increased plasma cell number ( J:191090 )

renal/urinary system

glomerulonephritis ( J:191090 )

• develop glomerulonephritis comparable to single Fcgr2b homozygotes

Genotype
MGI:3687459

cn32

• Allelic Composition: Dnmt1^tm2Jae/Dnmt1^tm2Jae; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S4/SvJae * BALB/c * C57BL/6

immune system

abnormal B cell differentiation ( J:113645 )

• there is complete block of B cell development in spleen and bone marrow

decreased pro-B cell number ( J:113645 )

• proportion of CD19+ lymphocytes is 10% compared to 74% in wild-type

hematopoietic system

abnormal B cell differentiation ( J:113645 )

• there is complete block of B cell development in spleen and bone marrow

decreased pro-B cell number ( J:113645 )

• proportion of CD19+ lymphocytes is 10% compared to 74% in wild-type

Genotype
MGI:5825469

cn33

• Allelic Composition: Cnn2^tm1.1Jin/Cnn2^tm1.1Jin; Cnn3^tm1.1Hjum/Cnn3^tm1.1Hjum; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S6/SvEvTac * 129X1/SvJ * BALB/c

immune system

immune system phenotype ( J:237712 )

N • mice exhibit normal formation of precursor and mature B cell populations

Genotype
MGI:5825467

cn34

• Allelic Composition: Cnn3^tm1.1Hjum/Cnn3^tm1.1Hjum; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S6/SvEvTac * BALB/c

immune system

immune system phenotype ( J:237712 )

N • mice exhibit normal early B cell development

Genotype
MGI:5301627

cn35

• Allelic Composition: Gt(ROSA)26Sor^{tm2(CAG-Notch2*)Uzs}/Gt(ROSA)26Sor⁺; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S6/SvEvTac * BALB/c * C57BL/6J

immune system

arrested B cell differentiation ( J:179036 )

• B cell development is blocked at pro-B cell stage

decreased B cell number ( J:179036 )

• in the spleen, inguinal lymph nodes, and peritoneal cavity

increased T cell number ( J:179036 )

decreased splenocyte number ( J:179036 )

hematopoietic system

arrested B cell differentiation ( J:179036 )

• B cell development is blocked at pro-B cell stage

increased bone marrow cell number ( J:179036 )

• slightly

decreased B cell number ( J:179036 )

• in the spleen, inguinal lymph nodes, and peritoneal cavity

increased T cell number ( J:179036 )

decreased splenocyte number ( J:179036 )

Genotype
MGI:5569496

cn36

• Allelic Composition: Ssb^tm1Rjma/Ssb^tm2.1Rjma; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: 129S/SvEv * BALB/c

immune system

immune system phenotype ( J:207687 )

N • mice exhibit normal splenic CD4+ and CD8+ T cells

arrested B cell differentiation ( J:207687 )

• total block at the pro-B cell to pre-B cell transition

decreased B cell number ( J:207687 )

• severe

small spleen ( J:207687 )

• hyposplenia

decreased spleen weight ( J:207687 )

decreased IgG level ( J:207687 )

• absent

decreased IgM level ( J:207687 )

• absent

hematopoietic system

arrested B cell differentiation ( J:207687 )

• total block at the pro-B cell to pre-B cell transition

decreased B cell number ( J:207687 )

• severe

small spleen ( J:207687 )

• hyposplenia

decreased spleen weight ( J:207687 )

decreased IgG level ( J:207687 )

• absent

decreased IgM level ( J:207687 )

• absent

Genotype
MGI:3687456

cn37

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Gt(ROSA)26Sor^tm1(EYFP)Cos/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129X1/SvJ * BALB/c * C57BL/6

homeostasis/metabolism

abnormal enzyme/coenzyme activity ( J:113645 )

• 97% of B lineage cells are EYFP-positive compared with 33% in Cd19^tm1(cre)Cgn-expressing mice indicating more efficient loxP recombination in developing B cells

Genotype
MGI:3797393

cn38

• Allelic Composition: Dicer1^tm1Mmk/Dicer1^tm1Mmk; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c

immune system

decreased immature B cell number ( J:135783 )

• hardly detected

increased pro-B cell number ( J:135783 )

• in the bone marrow

arrested B cell differentiation ( J:135783 )

• B cell development is almost completely blocked at the pro- to pre-B cell transition

decreased mature B cell number ( J:135783 )

• hardly detected

decreased pre-B cell number ( J:135783 )

• in the bone marrow due to a massive increase in apoptosis

hematopoietic system

decreased immature B cell number ( J:135783 )

• hardly detected

increased pro-B cell number ( J:135783 )

• in the bone marrow

arrested B cell differentiation ( J:135783 )

• B cell development is almost completely blocked at the pro- to pre-B cell transition

decreased mature B cell number ( J:135783 )

• hardly detected

decreased pre-B cell number ( J:135783 )

• in the bone marrow due to a massive increase in apoptosis

Genotype
MGI:5295256

cn39

• Allelic Composition: Nfatc1^tm1Rao/Nfatc1^tm1Rao; Nfatc2^tm1Rao/Nfatc2^tm1Rao; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c

immune system

abnormal B cell physiology ( J:177319 )

• stimulated B cells exhibit reduced ability to induced T cell proliferation

decreased interleukin-2 secretion ( J:177319 )

• from stimulated B cells

hematopoietic system

abnormal B cell physiology ( J:177319 )

• stimulated B cells exhibit reduced ability to induced T cell proliferation

Genotype
MGI:5295253

cn40

• Allelic Composition: Nfatc1^tm1Rao/Nfatc1^tm1Rao; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c

homeostasis/metabolism

abnormal B cell calcium ion homeostasis ( J:177319 )

• B cells exhibit reduced alpha-IgM-mediated calcium flux compared with control cells

immune system

increased B cell apoptosis ( J:177319 )

• alpha-IgM-mediated

decreased B cell proliferation ( J:177319 )

• following BCR-induction

• mild defects in alpha-IgM-mediated proliferation

abnormal class switch recombination ( J:177319 )

• to IgG3 induced by T cell-independent type II antigens

decreased B cell number ( J:177319 )

• in the spleen

decreased B-1a cell number ( J:177319 )

• 5- to 10-fold in peritoneal washes

abnormal B cell calcium ion homeostasis ( J:177319 )

• B cells exhibit reduced alpha-IgM-mediated calcium flux compared with control cells

abnormal marginal zone B cell physiology ( J:177319 )

• marginal zone B cells exhibit decreased TNP-Ficoll binding compared with wild-type cells

decreased susceptibility to experimental autoimmune encephalomyelitis ( J:177319 )

hematopoietic system

increased B cell apoptosis ( J:177319 )

• alpha-IgM-mediated

decreased B cell proliferation ( J:177319 )

• following BCR-induction

• mild defects in alpha-IgM-mediated proliferation

abnormal class switch recombination ( J:177319 )

• to IgG3 induced by T cell-independent type II antigens

decreased B cell number ( J:177319 )

• in the spleen

decreased B-1a cell number ( J:177319 )

• 5- to 10-fold in peritoneal washes

abnormal B cell calcium ion homeostasis ( J:177319 )

• B cells exhibit reduced alpha-IgM-mediated calcium flux compared with control cells

abnormal marginal zone B cell physiology ( J:177319 )

• marginal zone B cells exhibit decreased TNP-Ficoll binding compared with wild-type cells

cellular

increased B cell apoptosis ( J:177319 )

• alpha-IgM-mediated

decreased B cell proliferation ( J:177319 )

• following BCR-induction

• mild defects in alpha-IgM-mediated proliferation

Genotype
MGI:3797392

cn41

• Allelic Composition: Dicer1^tm1Mmk/Dicer1^tm1.1Mmk; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c

immune system

abnormal immunoglobulin V(D)J recombination ( J:135783 )

• usage of Dh elements and N nucleotide insertion into Igkappa is increased compared to in wild-type mice

decreased B cell number ( J:135783 )

hematopoietic system

abnormal immunoglobulin V(D)J recombination ( J:135783 )

• usage of Dh elements and N nucleotide insertion into Igkappa is increased compared to in wild-type mice

decreased B cell number ( J:135783 )

Genotype
MGI:3797394

cn42

• Allelic Composition: Dicer1^tm1Mmk/Dicer1^tm1Mmk; Tg(IghelMD4)4Ccg/0; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c

immune system

decreased B cell number ( J:135783 )

• while B cell numbers are increased relative to in Cd79a^tm1(cre)Reth/Cd79a⁺ Dicer1^tm1Mmk/Dicer1^tm1Mmk mice, numbers are still lower than in wild-type mice

decreased mature B cell number ( J:135783 )

hematopoietic system

decreased B cell number ( J:135783 )

• while B cell numbers are increased relative to in Cd79a^tm1(cre)Reth/Cd79a⁺ Dicer1^tm1Mmk/Dicer1^tm1Mmk mice, numbers are still lower than in wild-type mice

decreased mature B cell number ( J:135783 )

Genotype
MGI:4949890

cn43

• Allelic Composition: Grb2^tm1Lnit/Grb2^tm1Lnit; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * BALB/cJ

immune system

abnormal B cell differentiation ( J:171222 )

• in an adoptive transfer experiment, B cells are at a competitive disadvantage to wild-type B cells

decreased transitional stage T1 B cell number ( J:171222 )

decreased transitional stage T2 B cell number ( J:171222 )

increased plasma cell number ( J:171222 )

• IgM-secreting plasma cells

decreased B cell number ( J:171222 )

• in peripheral blood

decreased mature B cell number ( J:171222 )

• mice exhibit a reduction in recirculating, mature (IgM+B220^hi fraction F) B cells in the bone marrow compared with Grb2^tm1Lnit homozygote controls

• the number of mature B cells in the spleen is half that in wild-type mice

• however, mice exhibit normal numbers of marginal zone B cells and B1 cells in the spleen and peritoneal cavity

decreased follicular B cell number ( J:171222 )

decreased spleen germinal center number ( J:171222 )

• in mice immunized with sheep red blood cell

decreased spleen germinal center size ( J:171222 )

• in mice immunized with sheep red blood cell

abnormal B cell physiology ( J:171222 )

• mice exhibit reduced Brd-U labeled T1/marginal zone B cells compared with cells from Grb2^tm1Lnit homozygote controls

• however, bone marrow pre-B and immature B cell proliferation is normal

increased B cell apoptosis ( J:171222 )

• immature and mature B cells exhibit a slight increase in spontaneous apoptosis compared to in Grb2^tm1Lnit homozygote controls

increased B cell proliferation ( J:171222 )

• after anti-IgM or LPS stimulation

decreased IgG level ( J:171222 )

• in response to secondary exposure to human cytomegalovirus-derived virus-like particles

• however, primary IgG response is normal

decreased IgG3 level ( J:171222 )

• in TNP-ficoll treated mice

increased IgM level ( J:171222 )

• 10-fold in unstimulated mice

• however, IgM response to TNP-ficoll is normal

abnormal memory B cell physiology ( J:171222 )

• mice exhibit impaired memory response to human cytomegalovirus-derived virus-like particles compared with Grb2^tm1Lnit homozygote controls

hematopoietic system

abnormal B cell differentiation ( J:171222 )

• in an adoptive transfer experiment, B cells are at a competitive disadvantage to wild-type B cells

decreased transitional stage T1 B cell number ( J:171222 )

decreased transitional stage T2 B cell number ( J:171222 )

increased plasma cell number ( J:171222 )

• IgM-secreting plasma cells

decreased B cell number ( J:171222 )

• in peripheral blood

decreased mature B cell number ( J:171222 )

• mice exhibit a reduction in recirculating, mature (IgM+B220^hi fraction F) B cells in the bone marrow compared with Grb2^tm1Lnit homozygote controls

• the number of mature B cells in the spleen is half that in wild-type mice

• however, mice exhibit normal numbers of marginal zone B cells and B1 cells in the spleen and peritoneal cavity

decreased follicular B cell number ( J:171222 )

decreased spleen germinal center number ( J:171222 )

• in mice immunized with sheep red blood cell

decreased spleen germinal center size ( J:171222 )

• in mice immunized with sheep red blood cell

abnormal B cell physiology ( J:171222 )

• mice exhibit reduced Brd-U labeled T1/marginal zone B cells compared with cells from Grb2^tm1Lnit homozygote controls

• however, bone marrow pre-B and immature B cell proliferation is normal

increased B cell apoptosis ( J:171222 )

• immature and mature B cells exhibit a slight increase in spontaneous apoptosis compared to in Grb2^tm1Lnit homozygote controls

increased B cell proliferation ( J:171222 )

• after anti-IgM or LPS stimulation

decreased IgG level ( J:171222 )

• in response to secondary exposure to human cytomegalovirus-derived virus-like particles

• however, primary IgG response is normal

decreased IgG3 level ( J:171222 )

• in TNP-ficoll treated mice

increased IgM level ( J:171222 )

• 10-fold in unstimulated mice

• however, IgM response to TNP-ficoll is normal

abnormal memory B cell physiology ( J:171222 )

• mice exhibit impaired memory response to human cytomegalovirus-derived virus-like particles compared with Grb2^tm1Lnit homozygote controls

cellular

increased B cell apoptosis ( J:171222 )

• immature and mature B cells exhibit a slight increase in spontaneous apoptosis compared to in Grb2^tm1Lnit homozygote controls

increased B cell proliferation ( J:171222 )

• after anti-IgM or LPS stimulation

Genotype
MGI:3687508

cn44

• Allelic Composition: Ikbkg^tm1.1Mpa/Ikbkg^tm1.1Mpa; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

immune system

abnormal B cell differentiation ( J:113365 )

♀ • there is a pronounced block in B cell development at transition stage 1 in the spleen

decreased B cell number ( J:113365 )

♀ • mice show dramatic reduction in peripheral B cell numbers

decreased mature B cell number ( J:113365 )

♀ • numbers of mature B cells are reduced to 10% of levels in controls

hematopoietic system

abnormal B cell differentiation ( J:113365 )

♀ • there is a pronounced block in B cell development at transition stage 1 in the spleen

decreased B cell number ( J:113365 )

♀ • mice show dramatic reduction in peripheral B cell numbers

decreased mature B cell number ( J:113365 )

♀ • numbers of mature B cells are reduced to 10% of levels in controls

Genotype
MGI:5463972

cn45

• Allelic Composition: Atmin^tm1.2Jhh/Atmin^tm1.2Jhh; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

Small spleen size in Atmin^tm1.2Jhh/Atmin^tm1.2Jhh/ Cd79a^tm1(cre)Reth/Cd79a⁺ mice

immune system

abnormal B cell differentiation ( J:191832 )

• impaired in a cell-intrinsic manner

• not rescued by provision of a prearranged BCR

decreased immature B cell number ( J:191832 )

• more than 7-fold in the bone marrow

decreased mature B cell number ( J:191832 )

• more than 7-fold in the spleen

decreased pre-B cell number ( J:191832 )

• 3-fold in the bone marrow

small spleen ( J:191832 )

• 2-fold

decreased spleen weight ( J:191832 )

abnormal B cell physiology ( J:191832 )

• immature and transitional B cells exhibit a 3-fold increase in cell death compared with control cells

hematopoietic system

abnormal B cell differentiation ( J:191832 )

• impaired in a cell-intrinsic manner

• not rescued by provision of a prearranged BCR

decreased immature B cell number ( J:191832 )

• more than 7-fold in the bone marrow

decreased mature B cell number ( J:191832 )

• more than 7-fold in the spleen

decreased pre-B cell number ( J:191832 )

• 3-fold in the bone marrow

small spleen ( J:191832 )

• 2-fold

decreased spleen weight ( J:191832 )

abnormal B cell physiology ( J:191832 )

• immature and transitional B cells exhibit a 3-fold increase in cell death compared with control cells

Genotype
MGI:5501491

cn46

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Nfkbiz^tm1.1Muta/Nfkbiz^tm1.1Muta
• Genetic Background: involves: BALB/c * C57BL/6

immune system

immune system phenotype ( J:194832 )

N • lack inflammation up to 30 weeks of age

Genotype
MGI:5319484

cn47

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Was^tm1.1Ldn/Was^tm1.1Ldn
• Genetic Background: involves: BALB/c * C57BL/6

immune system

increased germinal center B cell number ( J:182528 )

♀ • in the spleen and lymph nodes

increased plasma cell number ( J:182528 )

♀ • increase in the proportion of CD19+ CD138^hi plasma cells

decreased B cell number ( J:182528 )

♀ • B cell lymphopenia

decreased mature B cell number ( J:182528 )

♀ • decrease in the percentage and absolute number of bone marrow B220 hi mature recirculating B cells

♀ • decrease in the proportion and number of CD19+ B cells in the spleen

decreased follicular B cell number ( J:182528 )

♀ • decrease in absolute number but not the proportion of follicular B cells

decreased marginal zone B cell number ( J:182528 )

♀ • decrease in the percentage and absolute number of marginal zone B cells

♀ • the ring of B220+ CD1d+ MZ B cells that normally surrounds MOMA-expressing metallophilic macrophages is almost absent

abnormal B cell physiology ( J:182528 )

♀ • virtual abrogation of IgM and IgG pneumococcus polysaccharide specific Ab responses

♀ • abrogation of the early response to immunization with UV inactivated vesicular stomatitis virus

increased IgM level ( J:182528 )

♀ • elevated total serum levels and spontaneous production of IgM Abs specific for trinitrophenyl and phosphocholine

increased autoantibody level ( J:182528 )

♀

increased anti-chromatin antibody level ( J:182528 )

♀

increased anti-double stranded DNA antibody level ( J:182528 )

♀

increased anti-single stranded DNA antibody level ( J:182528 )

♀

renal/urinary system

abnormal renal corpuscle morphology ( J:182528 )

♀ • modest degree of glomerular damage

hematopoietic system

increased germinal center B cell number ( J:182528 )

♀ • in the spleen and lymph nodes

increased plasma cell number ( J:182528 )

♀ • increase in the proportion of CD19+ CD138^hi plasma cells

decreased B cell number ( J:182528 )

♀ • B cell lymphopenia

decreased mature B cell number ( J:182528 )

♀ • decrease in the percentage and absolute number of bone marrow B220 hi mature recirculating B cells

♀ • decrease in the proportion and number of CD19+ B cells in the spleen

decreased follicular B cell number ( J:182528 )

♀ • decrease in absolute number but not the proportion of follicular B cells

decreased marginal zone B cell number ( J:182528 )

♀ • decrease in the percentage and absolute number of marginal zone B cells

♀ • the ring of B220+ CD1d+ MZ B cells that normally surrounds MOMA-expressing metallophilic macrophages is almost absent

abnormal B cell physiology ( J:182528 )

♀ • virtual abrogation of IgM and IgG pneumococcus polysaccharide specific Ab responses

♀ • abrogation of the early response to immunization with UV inactivated vesicular stomatitis virus

increased IgM level ( J:182528 )

♀ • elevated total serum levels and spontaneous production of IgM Abs specific for trinitrophenyl and phosphocholine

Genotype
MGI:5008567

cn48

• Allelic Composition: Stim1^tm1Kuro/Stim1^tm1Kuro; Stim2^tm1.1Kuro/Stim2^tm1.1Kuro; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

homeostasis/metabolism

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit little calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

immune system

immune system phenotype ( J:172608 )

N • mice exhibit normal B cell development

increased CD4-positive, alpha-beta T cell number ( J:172608 )

• following immunization with MOG35-55

increased CD8-positive, alpha-beta T cell number ( J:172608 )

• following immunization with MOG35-55

increased regulatory T cell number ( J:172608 )

• following immunization with MOG35-55

abnormal B cell physiology ( J:172608 )

• B cells treated with anti-IgM, anti-IgM and IL4, or anti-IgM and anti-CD40 exhibit reduced survival compared with control cells

• however, B cell treated with anti-CD40 or LPS exhibit normal survival and B cell antibody response is normal

decreased B cell proliferation ( J:172608 )

• B cells treated anti-IgM fail to exhibit proliferation unlike control cells

• B cells treated anti-IgM and IL4 exhibit reduced proliferation compared with control cells

• however, B cell proliferation stimulated by anti-CD40 or LPS is normal

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit little calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

increased interferon-gamma secretion ( J:172608 )

• in splenocytes following immunization with MOG35-55

decreased interleukin-10 secretion ( J:172608 )

• following stimulation with PMA and ionomycin, LPS, anti-IgM and anti-CD40, or anti-IgM and LPS

increased interleukin-10 secretion ( J:172608 )

• in splenocytes following immunization with MOG35-55

increased interleukin-17 secretion ( J:172608 )

• in splenocytes following immunization with MOG35-55

increased susceptibility to experimental autoimmune encephalomyelitis ( J:172608 )

• following immunization with MOG35-55, mice exhibit increased inflammatory cells infiltration (CD8+ and CD4+ T cells, T regulatory cells), demyelination, and cytokine production (IFN-gamma, IL17, and IL10) compared with control mice

nervous system

demyelination ( J:172608 )

• following immunization with MOG35-55

hematopoietic system

increased CD4-positive, alpha-beta T cell number ( J:172608 )

• following immunization with MOG35-55

increased CD8-positive, alpha-beta T cell number ( J:172608 )

• following immunization with MOG35-55

increased regulatory T cell number ( J:172608 )

• following immunization with MOG35-55

abnormal B cell physiology ( J:172608 )

• B cells treated with anti-IgM, anti-IgM and IL4, or anti-IgM and anti-CD40 exhibit reduced survival compared with control cells

• however, B cell treated with anti-CD40 or LPS exhibit normal survival and B cell antibody response is normal

decreased B cell proliferation ( J:172608 )

• B cells treated anti-IgM fail to exhibit proliferation unlike control cells

• B cells treated anti-IgM and IL4 exhibit reduced proliferation compared with control cells

• however, B cell proliferation stimulated by anti-CD40 or LPS is normal

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit little calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

cellular

decreased B cell proliferation ( J:172608 )

• B cells treated anti-IgM fail to exhibit proliferation unlike control cells

• B cells treated anti-IgM and IL4 exhibit reduced proliferation compared with control cells

• however, B cell proliferation stimulated by anti-CD40 or LPS is normal

Genotype
MGI:5008566

cn49

• Allelic Composition: Stim1^tm1Kuro/Stim1^tm1Kuro; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

homeostasis/metabolism

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit less calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

immune system

decreased B cell proliferation ( J:172608 )

• anti-IgM-treated B cells exhibit decreased proliferation unlike control cells

• however, B cell proliferation stimulated by anti-CD40 or LPS is normal

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit less calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

decreased interleukin-10 secretion ( J:172608 )

• following PMA and ionomycin stimulation

hematopoietic system

decreased B cell proliferation ( J:172608 )

• anti-IgM-treated B cells exhibit decreased proliferation unlike control cells

• however, B cell proliferation stimulated by anti-CD40 or LPS is normal

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit less calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

cellular

decreased B cell proliferation ( J:172608 )

• anti-IgM-treated B cells exhibit decreased proliferation unlike control cells

• however, B cell proliferation stimulated by anti-CD40 or LPS is normal

Genotype
MGI:5574306

cn50

• Allelic Composition: Gt(ROSA)26Sor^{tm1.1(Ubc-BCL3)Sbn}/Gt(ROSA)26Sor⁺; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

immune system

decreased B cell proliferation ( J:207111 )

• slightly less in LPS-stimulated marginal zone

• however, proliferation of alphaIgM-stimulated follicular B cells is not significantly different from that of wild-type cells

decreased follicular B cell number ( J:207111 )

• FO I B cells

decreased marginal zone B cell number ( J:207111 )

increased follicular B cell number ( J:207111 )

• total and FO II B cells

hematopoietic system

decreased B cell proliferation ( J:207111 )

• slightly less in LPS-stimulated marginal zone

• however, proliferation of alphaIgM-stimulated follicular B cells is not significantly different from that of wild-type cells

decreased follicular B cell number ( J:207111 )

• FO I B cells

decreased marginal zone B cell number ( J:207111 )

increased follicular B cell number ( J:207111 )

• total and FO II B cells

cellular

decreased B cell proliferation ( J:207111 )

• slightly less in LPS-stimulated marginal zone

• however, proliferation of alphaIgM-stimulated follicular B cells is not significantly different from that of wild-type cells

Genotype
MGI:5825357

cn51

• Allelic Composition: Tcf3^tm1(PBX1)Mlc/Tcf3⁺; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

neoplasm

increased B cell acute lymphoblastic leukemia incidence ( J:226241 )

• mice develop acute leukemia with an incidence of 53% at 12 months of age

• leukemia cells are present in the bone marrow, spleen, lymph nodes and infiltrate multiple organs, including the CNS

• 94% of leukemias have a B cell precursor phenotype

hematopoietic system

enlarged spleen ( J:226241 )

• in leukemic mice

arrested B cell differentiation ( J:226241 )

• leukemic blasts are arrested at the pro/pre-B stage of B cell precursor differentiation

anemia ( J:226241 )

• in leukemic mice

thrombocytopenia ( J:226241 )

• in leukemic mice

decreased B cell number ( J:226241 )

• a lower percentage of B cells are seen in the peripheral blood over a 30 week period in healthy preleukemic mice

decreased immature B cell number ( J:226241 )

• decrease in immature and recirculating B cells in the bone marrow in healthy preleukemic mice

increased leukocyte cell number ( J:226241 )

• leukemic mice present with leukocytosis

immune system

enlarged spleen ( J:226241 )

• in leukemic mice

arrested B cell differentiation ( J:226241 )

• leukemic blasts are arrested at the pro/pre-B stage of B cell precursor differentiation

decreased B cell number ( J:226241 )

• a lower percentage of B cells are seen in the peripheral blood over a 30 week period in healthy preleukemic mice

decreased immature B cell number ( J:226241 )

• decrease in immature and recirculating B cells in the bone marrow in healthy preleukemic mice

increased leukocyte cell number ( J:226241 )

• leukemic mice present with leukocytosis

enlarged lymph nodes ( J:226241 )

• in leukemic mice

liver/biliary system

enlarged liver ( J:226241 )

• in leukemic mice

growth/size/body

enlarged liver ( J:226241 )

• in leukemic mice

enlarged spleen ( J:226241 )

• in leukemic mice

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
acute lymphoblastic leukemia		DOID:9952	OMIM:247640 OMIM:613065	J:226241

Genotype
MGI:5319485

cn52

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Was^tm1.1Ldn/Y
• Genetic Background: involves: BALB/c * C57BL/6

immune system

increased germinal center B cell number ( J:182528 )

♂ • in the spleen and lymph nodes

increased plasma cell number ( J:182528 )

♂ • increase in the proportion of CD19+ CD138^hi plasma cells

decreased B cell number ( J:182528 )

♂ • B cell lymphopenia

decreased mature B cell number ( J:182528 )

♂ • decrease in the percentage and absolute number of bone marrow B220 hi mature recirculating B cells

♂ • decrease in the proportion and number of CD19+ B cells in the spleen

decreased follicular B cell number ( J:182528 )

♂ • decrease in absolute number but not the proportion of follicular B cells

decreased marginal zone B cell number ( J:182528 )

♂ • decrease in the percentage and absolute number of marginal zone B cells

♂ • the ring of B220+ CD1d+ MZ B cells that normally surrounds MOMA-expressing metallophilic macrophages is almost absent

abnormal B cell physiology ( J:182528 )

♂ • virtual abrogation of IgM and IgG pneumococcus polysaccharide specific Ab responses

♂ • abrogation of the early response to immunization with UV inactivated vesicular stomatitis virus

increased IgM level ( J:182528 )

♂ • elevated total serum levels and spontaneous production of IgM Abs specific for trinitrophenyl and phosphocholine

increased autoantibody level ( J:182528 )

♂

increased anti-chromatin antibody level ( J:182528 )

♂

increased anti-double stranded DNA antibody level ( J:182528 )

♂

increased anti-single stranded DNA antibody level ( J:182528 )

♂

renal/urinary system

abnormal renal corpuscle morphology ( J:182528 )

♂ • modest degree of glomerular damage

hematopoietic system

increased germinal center B cell number ( J:182528 )

♂ • in the spleen and lymph nodes

increased plasma cell number ( J:182528 )

♂ • increase in the proportion of CD19+ CD138^hi plasma cells

decreased B cell number ( J:182528 )

♂ • B cell lymphopenia

decreased mature B cell number ( J:182528 )

♂ • decrease in the percentage and absolute number of bone marrow B220 hi mature recirculating B cells

♂ • decrease in the proportion and number of CD19+ B cells in the spleen

decreased follicular B cell number ( J:182528 )

♂ • decrease in absolute number but not the proportion of follicular B cells

decreased marginal zone B cell number ( J:182528 )

♂ • decrease in the percentage and absolute number of marginal zone B cells

♂ • the ring of B220+ CD1d+ MZ B cells that normally surrounds MOMA-expressing metallophilic macrophages is almost absent

abnormal B cell physiology ( J:182528 )

♂ • virtual abrogation of IgM and IgG pneumococcus polysaccharide specific Ab responses

♂ • abrogation of the early response to immunization with UV inactivated vesicular stomatitis virus

increased IgM level ( J:182528 )

♂ • elevated total serum levels and spontaneous production of IgM Abs specific for trinitrophenyl and phosphocholine

Genotype
MGI:5319486

cn53

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Was^tm1.1Ldn/Was⁺
• Genetic Background: involves: BALB/c * C57BL/6

immune system

abnormal B cell proliferation ( J:182528 )

♀ • increased proliferation in cells lacking expression of Was compared to cells expressing Was in the follicular and germinal center B cell populations

abnormal B cell number ( J:182528 )

♀ • while B cell numbers are similar to controls, the distribution of cells lacking expression of Was is biased against marginal zone B cells

♀ • enrichment of null cells in the germinal center cell and plasma cell populations

hematopoietic system

abnormal B cell proliferation ( J:182528 )

♀ • increased proliferation in cells lacking expression of Was compared to cells expressing Was in the follicular and germinal center B cell populations

abnormal B cell number ( J:182528 )

♀ • while B cell numbers are similar to controls, the distribution of cells lacking expression of Was is biased against marginal zone B cells

♀ • enrichment of null cells in the germinal center cell and plasma cell populations

cellular

abnormal B cell proliferation ( J:182528 )

♀ • increased proliferation in cells lacking expression of Was compared to cells expressing Was in the follicular and germinal center B cell populations

Genotype
MGI:5008568

cn54

• Allelic Composition: Stim2^tm1.1Kuro/Stim2^tm1.1Kuro; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6

immune system

immune system phenotype ( J:172608 )

N • B cell proliferation in response to anti-IgM, anti-CD40, and LPS is normal

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit a mild decrease in calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

homeostasis/metabolism

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit a mild decrease in calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

hematopoietic system

abnormal B cell calcium ion homeostasis ( J:172608 )

• B cells exhibit a mild decrease in calcium ion influx after treatment with thapsigargin or anti-IgM compared with control mice

Genotype
MGI:7611733

cn55

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Phf5a^tm1.1Oux/Phf5a^tm1.1Oux; Tg(IghelMD4)4Ccg/0
• Genetic Background: involves: BALB/c * C57BL/6 * C57BL/6J

hematopoietic system

abnormal B cell number ( J:345807 )

• addition of a pre-rearranged IgH transgene partially but significantly increases the number of CD19+ B cells

immune system

abnormal B cell number ( J:345807 )

• addition of a pre-rearranged IgH transgene partially but significantly increases the number of CD19+ B cells

Genotype
MGI:5461328

cn56

• Allelic Composition: Bcl6^tm1.1Mtto/Bcl6^tm1.1Mtto; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6 * C57BL/6JJcl

immune system

abnormal somatic hypermutation frequency ( J:190943 )

• memory B cells from mice immunized with NP-CG fail to undergo somatic hypermutation compared with wild-type mice

decreased germinal center B cell number ( J:190943 )

• in mice immunized with NP-CG at day 5 and 7 (200-fold)

abnormal memory B cell morphology ( J:190943 )

• early germinal center memory B cells from mice immunized with NP-CG exhibit a resting state compared with wild-type mice

• however, the number of memory B cells is normal

abnormal memory B cell physiology ( J:190943 )

• 40 days after immunization with NP-CG, GC-independent memory B cells arise from dividing precursors, fail to exhibit a decrease in proliferation unlike wild-type cells and enter the memory compartment before germinal B cell progeny

abnormal humoral immune response ( J:190943 )

• memory B cells from mice treated with NP-CG produce low affinity antibodies in an IgG1 secondary response unlike wild-type cells

hematopoietic system

abnormal somatic hypermutation frequency ( J:190943 )

• memory B cells from mice immunized with NP-CG fail to undergo somatic hypermutation compared with wild-type mice

decreased germinal center B cell number ( J:190943 )

• in mice immunized with NP-CG at day 5 and 7 (200-fold)

abnormal memory B cell morphology ( J:190943 )

• early germinal center memory B cells from mice immunized with NP-CG exhibit a resting state compared with wild-type mice

• however, the number of memory B cells is normal

abnormal memory B cell physiology ( J:190943 )

• 40 days after immunization with NP-CG, GC-independent memory B cells arise from dividing precursors, fail to exhibit a decrease in proliferation unlike wild-type cells and enter the memory compartment before germinal B cell progeny

Genotype
MGI:5461331

cn57

• Allelic Composition: Bcl6^tm1.1Mtto/Bcl6^tm1.1Mtto; Cd79a^tm1(cre)Reth/Cd79a⁺; Tg(Cd4-cre)1Cwi/0
• Genetic Background: involves: BALB/c * C57BL/6 * C57BL/6JJcl * DBA/2

immune system

immune system phenotype ( J:190943 )

N • mice immunized with NP-CG exhibit normal development of memory B cells

decreased germinal center B cell number ( J:190943 )

• in mice immunized with NP-CG

hematopoietic system

decreased germinal center B cell number ( J:190943 )

• in mice immunized with NP-CG

Genotype
MGI:7646989

cn58

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Eif4b^tm1.1Tnr/Eif4b^tm1.1Tnr; Eif4h^{tm1c(EUCOMM)Wtsi}/Eif4h^{tm1c(EUCOMM)Wtsi}
• Genetic Background: involves: BALB/c * C57BL/6 * C57BL/6N

hematopoietic system

hematopoietic system phenotype ( J:344730 )

N • 7 days after immunization with 4-hydroxy-3-nitrophenyl-acetyl conjugated to keyhole limpet hemocyanin B cell numbers are similar to immunized controls

decreased mature B cell number ( J:344730 )

• small reduction (25%) in mature/recirculating B cells

• normal numbers of splenic B cells and fractions of B-E B cells in the bone marrow

decreased IgG1 level ( J:344730 )

• small reduction in high-affinity IgG1 antibodies at 14 days after immunization with 4-hydroxy-3-nitrophenyl-acetyl conjugated to keyhole limpet hemocyanin

immune system

decreased mature B cell number ( J:344730 )

• small reduction (25%) in mature/recirculating B cells

• normal numbers of splenic B cells and fractions of B-E B cells in the bone marrow

decreased IgG1 level ( J:344730 )

• small reduction in high-affinity IgG1 antibodies at 14 days after immunization with 4-hydroxy-3-nitrophenyl-acetyl conjugated to keyhole limpet hemocyanin

Genotype
MGI:7611716

cn59

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Phf5a^tm1.1Oux/Phf5a^tm1.1Oux
• Genetic Background: involves: BALB/c * C57BL/6J

hematopoietic system

abnormal B cell receptor editing ( J:345807 )

• defect in RAG-mediated recombination

abnormal immunoglobulin heavy chain V(D)J recombination ( J:345807 )

• significant reduction in the diversity of IgH chain repetoires

decreased early pro-B cell number ( J:345807 )

• decreased absolute numbers of BP1- CD24+ early pro-B cells

decreased late pro-B cell number ( J:345807 )

• decreased absolute numbers of BP1+ CD24^high late pro-B cells

increased pre-pro B cell number ( J:345807 )

• increase in frequency and absolute number of BP1- CD24- pre-pro-B cells

• no increase in proliferation of pre-pro-B cells

decreased B cell number ( J:345807 )

• approximately sixfold decrease in both percentage and total number of B220+ B cells in the bone marrow

• percentages and absolute numbers of B220+ CD43- late-stage B cells and B220^high CD43- recirculating B cells are decreased

• severe B lymphopenia in the periphery

decreased immature B cell number ( J:345807 )

• drastically reduced B220+ CD43+ IgM+ IgD- immature B cell numbers

decreased mature B cell number ( J:345807 )

• dramatic reduction in the number of B220+ splenic B cells

• IgD+ mature B cells are virtually absent in the spleen

decreased pre-B cell number ( J:345807 )

• drastically reduced B220+ CD43- IgM- IgD- small pre-B cell numbers

small spleen ( J:345807 )

abnormal B cell physiology ( J:345807 )

• defect in IgH chain gene expression in pre-pro-B cells

immune system

abnormal B cell receptor editing ( J:345807 )

• defect in RAG-mediated recombination

abnormal immunoglobulin heavy chain V(D)J recombination ( J:345807 )

• significant reduction in the diversity of IgH chain repetoires

decreased early pro-B cell number ( J:345807 )

• decreased absolute numbers of BP1- CD24+ early pro-B cells

decreased late pro-B cell number ( J:345807 )

• decreased absolute numbers of BP1+ CD24^high late pro-B cells

increased pre-pro B cell number ( J:345807 )

• increase in frequency and absolute number of BP1- CD24- pre-pro-B cells

• no increase in proliferation of pre-pro-B cells

decreased B cell number ( J:345807 )

• approximately sixfold decrease in both percentage and total number of B220+ B cells in the bone marrow

• percentages and absolute numbers of B220+ CD43- late-stage B cells and B220^high CD43- recirculating B cells are decreased

• severe B lymphopenia in the periphery

decreased immature B cell number ( J:345807 )

• drastically reduced B220+ CD43+ IgM+ IgD- immature B cell numbers

decreased mature B cell number ( J:345807 )

• dramatic reduction in the number of B220+ splenic B cells

• IgD+ mature B cells are virtually absent in the spleen

decreased pre-B cell number ( J:345807 )

• drastically reduced B220+ CD43- IgM- IgD- small pre-B cell numbers

small spleen ( J:345807 )

abnormal B cell physiology ( J:345807 )

• defect in IgH chain gene expression in pre-pro-B cells

Genotype
MGI:7625698

cn60

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Orai1^tm1Smua/Orai1^tm1Smua
• Genetic Background: involves: BALB/c * C57BL/6J

immune system

immune system phenotype ( J:345485 )

N • no defects in B cell development in the bone marrow or spleen

abnormal B cell physiology ( J:345485 )

• store-operated Ca2+ entry (SOCE) in B cells is reduced by~69%

• however, agonist induced Ca2+ oscillations are similar to controls

• residual SOCE activity is not inhibited by 2-aminoethyl diphenyl borate (2-APB)

• anti-IgM mediated NFAT1 translocation is significantly reduced

abnormal B cell activation ( J:345485 )

• following anti-IgM stimulation proliferation is similar to controls but cell viability is moderately reduced

• increase in oxygen consumption rate and extracellular acidification rates following B cell receptor activation is significantly blunted

homeostasis/metabolism

abnormal calcium ion homeostasis ( J:345485 )

• store-operated Ca2+ entry (SOCE) in B cells is reduced by~69%

• residual SOCE activity in B cells is not inhibited by 2-aminoethyl diphenyl borate (2-APB)

• however, agonist induced Ca2+ oscillations in B cells are similar to controls

hematopoietic system

abnormal B cell physiology ( J:345485 )

• store-operated Ca2+ entry (SOCE) in B cells is reduced by~69%

• however, agonist induced Ca2+ oscillations are similar to controls

• residual SOCE activity is not inhibited by 2-aminoethyl diphenyl borate (2-APB)

• anti-IgM mediated NFAT1 translocation is significantly reduced

abnormal B cell activation ( J:345485 )

• following anti-IgM stimulation proliferation is similar to controls but cell viability is moderately reduced

• increase in oxygen consumption rate and extracellular acidification rates following B cell receptor activation is significantly blunted

Genotype
MGI:7625702

cn61

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Orai1^tm1Smua/Orai1^tm1Smua; Orai3^em1.1Treb/Orai3^em1.1Treb
• Genetic Background: involves: BALB/c * C57BL/6J * C57BL/6N

immune system

immune system phenotype ( J:345485 )

N • immune responses to influenza A infection are similar to controls

abnormal B cell physiology ( J:345485 )

• store-operated Ca2+ entry in B cells is reduced by~83%

• anti-IgM mediated NFAT1 translocation is significantly reduced

abnormal B cell activation ( J:345485 )

• increase in oxygen consumption rate and extracellular acidification rates following B cell receptor activation is significantly blunted

decreased B cell proliferation ( J:345485 )

• decrease in both proliferation and viablity of cells following anti-IgM stimulation

hematopoietic system

abnormal B cell physiology ( J:345485 )

• store-operated Ca2+ entry in B cells is reduced by~83%

• anti-IgM mediated NFAT1 translocation is significantly reduced

abnormal B cell activation ( J:345485 )

• increase in oxygen consumption rate and extracellular acidification rates following B cell receptor activation is significantly blunted

decreased B cell proliferation ( J:345485 )

• decrease in both proliferation and viablity of cells following anti-IgM stimulation

homeostasis/metabolism

abnormal calcium ion homeostasis ( J:345485 )

• store-operated Ca2+ entry in B cells is reduced by~83%

cellular

decreased B cell proliferation ( J:345485 )

• decrease in both proliferation and viablity of cells following anti-IgM stimulation

Genotype
MGI:7625703

cn62

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Orai3^em1.1Treb/Orai3^em1.1Treb
• Genetic Background: involves: BALB/c * C57BL/6J * C57BL/6N

immune system

immune system phenotype ( J:345485 )

N • store-operated Ca2+ entry in B cells is not significantly different from controls

abnormal B cell activation ( J:345485 )

• anti-IgM stimulated proliferation is similar to control but viability is increased

hematopoietic system

abnormal B cell activation ( J:345485 )

• anti-IgM stimulated proliferation is similar to control but viability is increased

Genotype
MGI:3797395

cn63

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Dicer1^tm1Mmk/Dicer1^tm1Mmk; Tg(BCL2)22Wehi/0
• Genetic Background: involves: BALB/c * C57BL/6JWehi * SJL/JWehi

immune system

decreased B cell number ( J:135783 )

• while B cell numbers are increased relative to in Cd79a^tm1(cre)Reth/Cd79a⁺ Dicer1^tm1Mmk/Dicer1^tm1Mmk mice, numbers are still lower than in wild-type mice

decreased mature B cell number ( J:135783 )

hematopoietic system

decreased B cell number ( J:135783 )

• while B cell numbers are increased relative to in Cd79a^tm1(cre)Reth/Cd79a⁺ Dicer1^tm1Mmk/Dicer1^tm1Mmk mice, numbers are still lower than in wild-type mice

decreased mature B cell number ( J:135783 )

Genotype
MGI:5550380

cn64

• Allelic Composition: Rnf31^tm1.1Kiwa/Rnf31^tm1.1Kiwa; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6NCrlj * CBA/JNCrlj

immune system

immune system phenotype ( J:201885 )

N • mice exhibit normal conventional B cell development and I cell populations

abnormal B-1 B cell morphology ( J:201885 )

• severely impaired B1 B cell development in the peritoneal cavity

decreased B-1a cell number ( J:201885 )

• in the peritoneal cavity

decreased B-1b cell number ( J:201885 )

• in the peritoneal cavity

abnormal humoral immune response ( J:201885 )

• impaired antibody responses to both T cell-dependent and T cell-independent type 2 antigens

decreased IgA level ( J:201885 )

• in unimmunized mice

decreased IgG1 level ( J:201885 )

• in unimmunized mice

• in mice immunized with NP-CGG

decreased IgG2a level ( J:201885 )

• in unimmunized mice

decreased IgG2b level ( J:201885 )

• in unimmunized mice

decreased IgG3 level ( J:201885 )

• in unimmunized mice

• in mice immunized with NP-Ficoll

decreased IgM level ( J:201885 )

• in unimmunized mice

• in mice immunized with NP-CGG or NP-Ficoll

hematopoietic system

abnormal B-1 B cell morphology ( J:201885 )

• severely impaired B1 B cell development in the peritoneal cavity

decreased B-1a cell number ( J:201885 )

• in the peritoneal cavity

decreased B-1b cell number ( J:201885 )

• in the peritoneal cavity

decreased IgA level ( J:201885 )

• in unimmunized mice

decreased IgG1 level ( J:201885 )

• in unimmunized mice

• in mice immunized with NP-CGG

decreased IgG2a level ( J:201885 )

• in unimmunized mice

decreased IgG2b level ( J:201885 )

• in unimmunized mice

decreased IgG3 level ( J:201885 )

• in unimmunized mice

• in mice immunized with NP-Ficoll

decreased IgM level ( J:201885 )

• in unimmunized mice

• in mice immunized with NP-CGG or NP-Ficoll

Genotype
MGI:6358355

cn65

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Commd3^tm1.1Ksuz/Commd3^tm1.1Ksuz
• Genetic Background: involves: BALB/c * C57BL/6NSlc * SJL

immune system

immune system phenotype ( J:278399 )

N • mice exhibit normal size of developing B cell subsets and serum levels of IgG3 and IgA in unimmunized mice

decreased mature B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

decreased follicular B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

abnormal plasmablast number ( J:278399 )

• decreased after immunization with NP-CGG compared with controls

abnormal spleen B cell follicle morphology ( J:278399 )

• less defined boundaries

decreased spleen germinal center number ( J:278399 )

• after immunization with NP-CGG compared with controls

abnormal follicular B cell physiology ( J:278399 )

• impaired B cell migration in response to CXCL12, CXCL13, CCL19 and 7alpha,25-HC

• bone marrow chimeras exhibit increased migration of B cells from follicles compared with wild-derived cells

• however, response to S1P is normal as is lymph node egression

decreased IgG1 level ( J:278399 )

• in unimmunized mice and after immunization with NP-CGG compared with controls

decreased IgG2b level ( J:278399 )

• in unimmunized mice

decreased IgG2c level ( J:278399 )

• in unimmunized mice

decreased IgM level ( J:278399 )

• in unimmunized mice and after immunization with NP-CGG compared with controls

hematopoietic system

decreased mature B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

decreased follicular B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

abnormal plasmablast number ( J:278399 )

• decreased after immunization with NP-CGG compared with controls

abnormal spleen B cell follicle morphology ( J:278399 )

• less defined boundaries

decreased spleen germinal center number ( J:278399 )

• after immunization with NP-CGG compared with controls

abnormal follicular B cell physiology ( J:278399 )

• impaired B cell migration in response to CXCL12, CXCL13, CCL19 and 7alpha,25-HC

• bone marrow chimeras exhibit increased migration of B cells from follicles compared with wild-derived cells

• however, response to S1P is normal as is lymph node egression

decreased IgG1 level ( J:278399 )

• in unimmunized mice and after immunization with NP-CGG compared with controls

decreased IgG2b level ( J:278399 )

• in unimmunized mice

decreased IgG2c level ( J:278399 )

• in unimmunized mice

decreased IgM level ( J:278399 )

• in unimmunized mice and after immunization with NP-CGG compared with controls

Genotype
MGI:6358356

cn66

• Allelic Composition: Cd79a^tm1(cre)Reth/Cd79a⁺; Commd8^tm1.1Ksuz/Commd8^tm1.1Ksuz
• Genetic Background: involves: BALB/c * C57BL/6NSlc * SJL

immune system

immune system phenotype ( J:278399 )

N • mice exhibit normal size of developing B cell subsets and serum levels of IgA in unimmunized mice

decreased mature B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

decreased follicular B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

abnormal plasmablast number ( J:278399 )

• decreased after immunization with NP-CGG compared with controls

abnormal spleen B cell follicle morphology ( J:278399 )

• less defined boundaries

decreased spleen germinal center number ( J:278399 )

• after immunization with NP-CGG compared with controls

abnormal follicular B cell physiology ( J:278399 )

• impaired B cell migration in response to CXCL12, CXCL13, CCL19 and 7alpha,25-HC

• bone marrow chimeras exhibit increased migration of B cells from follicles compared with wild-derived cells

• however, response to S1P is normal as is lymph node egression

decreased IgG1 level ( J:278399 )

• in unimmunized mice and after immunization with NP-CGG compared with controls

decreased IgG2b level ( J:278399 )

• in unimmunized mice

decreased IgG2c level ( J:278399 )

• in unimmunized mice

decreased IgG3 level ( J:278399 )

• in unimmunized mice

decreased IgM level ( J:278399 )

• after immunization with NP-CGG compared with controls

• however, unimmunized mice exhibit normal levels of IgM

hematopoietic system

decreased mature B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

decreased follicular B cell number ( J:278399 )

• in the bone marrow, blood, and spleen

abnormal plasmablast number ( J:278399 )

• decreased after immunization with NP-CGG compared with controls

abnormal spleen B cell follicle morphology ( J:278399 )

• less defined boundaries

decreased spleen germinal center number ( J:278399 )

• after immunization with NP-CGG compared with controls

abnormal follicular B cell physiology ( J:278399 )

• impaired B cell migration in response to CXCL12, CXCL13, CCL19 and 7alpha,25-HC

• bone marrow chimeras exhibit increased migration of B cells from follicles compared with wild-derived cells

• however, response to S1P is normal as is lymph node egression

decreased IgG1 level ( J:278399 )

• in unimmunized mice and after immunization with NP-CGG compared with controls

decreased IgG2b level ( J:278399 )

• in unimmunized mice

decreased IgG2c level ( J:278399 )

• in unimmunized mice

decreased IgG3 level ( J:278399 )

• in unimmunized mice

decreased IgM level ( J:278399 )

• after immunization with NP-CGG compared with controls

• however, unimmunized mice exhibit normal levels of IgM

Genotype
MGI:5296787

cn67

• Allelic Composition: Sh3kbp1^tm1Kuro/Sh3kbp1^tm1Kuro; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6 * NZB

immune system

immune system phenotype ( J:176805 )

♀N • no gross development arrest in bone marrow

abnormal lymphocyte cell number ( J:176805 )

♀

decreased B cell number ( J:176805 )

♀ • recirculating B cells reduced about 20%

decreased immature B cell number ( J:176805 )

♀ • reduced about 20%

decreased transitional stage T2 B cell number ( J:176805 )

♀ • reduced about 20% in the spleen

decreased transitional stage T3 B cell number ( J:176805 )

♀ • reduced about 20% in the spleen

decreased B-1a cell number ( J:176805 )

♀ • peritoneal B-1a B cells are reduced about 8 fold

decreased follicular B cell number ( J:176805 )

♀ • reduced about 20% in the spleen

abnormal B cell physiology ( J:176805 )

♀ • antigen specific B cells fail to increase due to T cell independent type II antibody response

♀ • B cell proliferation after anti-IgM stimulation is severely reduced

abnormal humoral immune response ( J:176805 )

♀ • T cell independent type II antibody responses are considerably reduced

hematopoietic system

abnormal lymphocyte cell number ( J:176805 )

♀

decreased B cell number ( J:176805 )

♀ • recirculating B cells reduced about 20%

decreased immature B cell number ( J:176805 )

♀ • reduced about 20%

decreased transitional stage T2 B cell number ( J:176805 )

♀ • reduced about 20% in the spleen

decreased transitional stage T3 B cell number ( J:176805 )

♀ • reduced about 20% in the spleen

decreased B-1a cell number ( J:176805 )

♀ • peritoneal B-1a B cells are reduced about 8 fold

decreased follicular B cell number ( J:176805 )

♀ • reduced about 20% in the spleen

abnormal B cell physiology ( J:176805 )

♀ • antigen specific B cells fail to increase due to T cell independent type II antibody response

♀ • B cell proliferation after anti-IgM stimulation is severely reduced

Genotype
MGI:5296788

cn68

• Allelic Composition: Sh3kbp1^tm1Kuro/Sh3kbp1^tm1Kuro; Cd79a^tm1(cre)Reth/Cd79a⁺; Gt(ROSA)26Sor^{tm4(Ikbkb)Rsky}/?
• Genetic Background: involves: BALB/c * C57BL/6 * NZB

immune system

immune system phenotype ( J:176805 )

♀N • T cell independent type II antibody responses are restored

decreased B-1a cell number ( J:176805 )

♀ • B-1a cell development continues to be defective

hematopoietic system

decreased B-1a cell number ( J:176805 )

♀ • B-1a cell development continues to be defective

Genotype
MGI:5316371

cn69

• Allelic Composition: Ebf1^tm1.1Rug/Ebf1^tm1.1Rug; Cd79a^tm1(cre)Reth/Cd79a⁺
• Genetic Background: involves: BALB/c * C57BL/6 * SJL

immune system

arrested B cell differentiation ( J:182210 )

• at the pre-pro-B cell stage, not rescued by over-expression of Bcl2

hematopoietic system

arrested B cell differentiation ( J:182210 )

• at the pre-pro-B cell stage, not rescued by over-expression of Bcl2